Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma
Status:
Terminated
Trial end date:
2018-10-08
Target enrollment:
Participant gender:
Summary
This is a pilot/feasibility study. The study design represents a modification of current
standard of care for Diffuse Intrinsic Pontine Glioma (DIPG) (5580 cGY involved field
radiation), with the final two doses of radiation given at intervals during the vaccination
phase of treatment.
Patients between the ages of 3 years and 25 years diagnosed with Diffuse Intrinsic Pontine
Glioma (DIPG) will be allowed to participate in the trial. Study enrollment will occur after
the completion of conformal radiation therapy to a dose of 5580 cGy and the post radiation
therapy (RT) magnetic resonance imaging (MRI) shows no disease progression.
Three patients with glioblastoma multiforme, aged 16 years and older, will be entered first
to confirm vaccine safety before enrolling DIPG patients.